Coronavirus / COVID

Sanofi and GSK’s booster vaccine candidate is modeled on the Beta COVID-19 variant, and increases Omicron-neutralizing antibody titers 40-fold.

Rather than developing vaccines for each new variant, some officials are pushing to follow the flu vaccine model, with annual vaccination.

Merck’s antiviral drug molnupiravir may benefit nonhospitalized patients with mild or moderate COVID-19, according to a secondary analysis of phase 3 clinical trial data.

Immunization against COVID-19 benefits pregnant women as well as their offspring.

AstraZeneca’s Evusheld, dual injections of tixagevimab and cilgavimab, reduced the risk of severe or fatal COVID-19 disease by 50%. When administered within 3 days of symptom onset, Evusheld had an 88% risk reduction.

Rebound in COVID-19 symptoms, retesting positive for SARS-CoV-2, and recurring infectivity after Paxlovid treatment mars "test and treat."

Moderna’s bivalent COVID-19 vaccine booster, mRNA-1273.214, generated nearly twice the protective antibodies against Omicron.

The vote was 21-0 in favor of an emergency use authorization (EUA), with one voter abstaining.

Impairment of cognitive function is a growing, concerning effect of "long COVID."

Adults living with HIV were more likely to have a breakthrough COVID-19 infection after vaccination, suggesting a need for additional vaccine doses in this population.

The advisory group is meeting on Tuesday to discuss the vaccine’s presenting data and a potential authorization.

New vaccine for COVID-19 employing receptor-binding domain-dimer-based platform achieves 87.6% efficacy against severe to critical illness.

The study authors determined that COVID-19 patients with HIV were 38% more likely to die than those without HIV.

COVID-19 mortality is most frequent in men 60-77 years old with acute lung injury.

The White House coronavirus response coordinator said vaccines for children under 5 could potentially begin on June 21.

New research in Israel offers hope that multisystem inflammatory syndrome in children—a serious complication of COVID-19—declined during the Omicron surge of the pandemic.

In 2020, COVID-19 mortality rates were 5 times higher among adults in low socioeconomic positions.

Synairgen's inhalable Interferon-beta treatment, SNG001, may be a treatment option for hospitalized and immunocompromised COVID-19 patients.

The organization is behind community-based funding and educational programs to propel a healthier society at a grassroots level.

Medical professionals discuss how they affect immunity as well as the necessity of these additional vaccinations.

This crisis has united multidisciplinary groups and laid the foundation to better equip the health care workforce for future pandemics.

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.

Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.

With few exceptions, COVID-19 therapies have not been studied comparatively, so choosing therapies to preferentially recommend is difficult and is done, instead, by strength of evidence and quality of data.

The need for safe and effective treatment against the various strains of COVID-19 increase, and investigators continue to assess various pharmacologic options.